Gain Therapeutics, Inc.
GANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819411
No open-market purchases or sales by Gain Therapeutics, Inc. insiders were filed in the last 90 days; 50 institutions reported holding it in 13F filings for Q2 2026, worth $17.4M in total; Greenlight Capital is the only superinvestor holding it.
Q2 2024 vs. Q1 2024
How the institutions holding Gain Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 26 | 28 | +2 |
| Shares | 1.87M | 3.04M | +1.17M (+62.6%) |
| Value | $7.04M | $3.89M | −$3.15M (−44.8%) |
New holders (8)
Institutions that held Gain Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Timelo Investment Management Inc. | 605,288 | $774.8K | 1.56% |
| Alyeska Investment Group, L.P. | 450,000 | $576.0K | 0.00% |
| Hohimer Wealth Management, LLC | 330,000 | $422.4K | 0.10% |
| Cable Car Capital LLC | 145,000 | $185.6K | 0.20% |
| Warberg Asset Management LLC | 51,600 | $65.5K | 0.02% |
| Virtu Financial LLC | 27,356 | $35.0K | 0.00% |
| Gilbert & Cook, Inc. | 10,000 | $12.8K | 0.00% |
| Jones Financial Companies LLLP | 7,000 | $8.96K | 0.00% |
Sold out (6)
Institutions that held Gain Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Raymond James & Associates | 260,019 | $980.3K |
| Susquehanna International Group, LLP | 43,062 | $162.3K |
| Citadel Advisors LLC | 4,223 | $15.9K |
| HM Payson & Co | 1,000 | $3.77K |
| Citigroup Inc | 684 | $2.58K |
| GWM Advisors LLC | 225 | $848 |